Kory James Wentworth, Chief Financial Officer at Entrada Therapeutics, Inc. (TRDA), sold 17,820 shares at $9.98 ($178K) on 2025-11-21, disclosed to the SEC on 2025-11-24.
Scheduled sale ($178k) by Chief Financial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $9.98 | 8,910 | $89K | 50.0% |
| 2 | $9.98 | 8,910 | $89K | 50.0% |
| Total | $9.98 avg | 17,820 | $178K | 100% |
| Filing → |
| TRDA | SELL | 2026-03-06 | $196K | — | Filing → |
| TRDA | SELL | 2025-03-19 | $19K | — | Filing → |
| TRDA | SELL | 2024-12-03 | $120K | — | Filing → |